A companion diagnostic is a predictive biomarker test, utilized to support dosing decision-making for patient stratification and treatment. It received global support and the market size is expected to double within the next 5 years. This webinar reviews the importance and regulatory success of companion diagnostic biomarker assays in currently approved drugs, as well as forecasting the trend and possible issues that might arise in the future. In addition, the outsourcing of companion diagnostic tests to a contract research lab will be discussed.
What will you learn?
* Importance and regulatory success of companion diagnostics
* Forecast of companion diagnostics and precision medicine in the future from multiple perspectives
* Companion diagnostic outsourcing strategy
Speaker: Kai Wang, Director of Bioanalytical and Biologics Services, Frontage Laboratories, Inc. (PA, USA)
Dr. Kai Wang is the Director of Bioanalytical and Biologics Services at Frontage Laboratories, Inc. (PA, USA) and is leading the biomarker services of Frontage. His current research focus is in the area of bioanalytical method development and validation of various types of biomarkers. Dr. Wang earned a doctor of philosophy degree in chemistry from Rutgers University (NJ, USA) – New Brunswick and received a bachelor of science degree in chemistry from Nanjing University (Nanjing, China).
Thank you for registering!
You may now view the resource below.
In this panel discussion, expert panelists, including Dr. Kai Wang, discuss the current state of precision medicine and companion diagnostics research. They provide insights into how they approach drug development research with a personalized approach and the role of companion diagnostics in this development. Panelists also review the state of current regulations regarding companion diagnostics in relation to laboratory-developed tests.